专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

WO2017123826A1 MAST-CELL MODULATORS AND USES THEREOF 审中-公开
标题翻译： MAST-CELL调制器及其用途
公开(公告)号：WO2017123826A1
公开(公告)日：2017-07-20
申请号：PCT/US2017/013279
申请日：2017-01-13
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： SUN, Lijun , VEVES, Aristidis
IPC分类号： C07D231/56 , C07D417/12 , C07D209/36 , A61K31/4439 , A61K31/404 , A61K31/416 , A61P29/00 , A61P3/10
CPC分类号： C07D209/36 , C07D231/56 , C07D417/12
摘要： Provided are novel compounds of Formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders associated with mast cells. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more diseases and disorders associated with mast cells.
摘要翻译：所提供的是式I的新型化合物，其药学上可接受的盐及其药物组合物，其可用于治疗与肥大细胞相关的疾病和病症。还提供了包含式I的新化合物的药物组合物及其用于治疗一种或多种与肥大细胞相关的疾病和病症的方法。

82. 发明申请

WO2017070515A2 METHODS OF PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASE WITH BRANCHED FATTY ACID ESTERS OF HYDROXY FATTY ACIDS (FAHFAS) 审中-公开
标题翻译：用羟基脂肪酸（FAHFAS）分支脂肪酸酯预防和治疗炎性肠病的方法
公开(公告)号：WO2017070515A2
公开(公告)日：2017-04-27
申请号：PCT/US2016/058184
申请日：2016-10-21
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , SALK INSTITUTE FOR BIOLOGICAL STUDIES , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人： KAHN, Barbara B. , SAGHATELIAN, Alan , LEE, Jennifer , MORAES-VIEIRA, Pedro M.
IPC分类号： A61K31/20
CPC分类号： A61K31/20 , A61K31/201
摘要： The invention provides a method and pharmaceutical composition useful in preventing and treating colitis with branched fatty acid esters of hydroxy fatty acids (FAHFAs). For example, the invention is related to the use of branched palmitic acid esters of hydroxy stearic acids (PAHS As), with beneficial metabolic and anti -inflammatory effects. The composition contains effective amounts of PAHS As and a pharmaceutically acceptable vehicle, carrier and/or diluent. The pharmaceutical compositions are prepared for oral administration in single or combination therapies.
摘要翻译：本发明提供可用于预防和治疗结肠炎的方法和药物组合物，其中用羟基脂肪酸的支链脂肪酸酯（FAHFA）来预防和治疗结肠炎。例如，本发明涉及使用羟基硬脂酸（PAHS As）的支化棕榈酸酯，具有有益的代谢和抗炎作用。该组合物含有有效量的PAHSAs和药学上可接受的载体，载体和/或稀释剂。制备药物组合物用于单一或联合治疗的口服给药。

83. 发明申请

WO2017027373A1 ESTIMATION OF DESCRIPTIVE PARAMETERS FROM A SAMPLE 审中-公开
标题翻译：从样本估计描述性参数
公开(公告)号：WO2017027373A1
公开(公告)日：2017-02-16
申请号：PCT/US2016/045760
申请日：2016-08-05
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： ARNAOUT, Ramy , KAPLINSKY, Joseph
IPC分类号： G06F19/24
CPC分类号： G06F19/24
摘要： An apparatus and method for generating a modified maximum-likelihood description of a system having a parent population of entities of different classes that includes collecting a sample population of the entities and measuring a statistical distribution of the sample population. The method further includes determining a modified maximum-likelihood estimate of the parent population based on the statistical distribution of the sample population and calculating a diversity measure of the estimated parent population to describe the system.
摘要翻译：一种用于生成具有不同类别的实体的母体群体的系统的修改的最大似然描述的装置和方法，包括收集实体的样本群并测量样本群体的统计分布。该方法还包括基于样本群体的统计分布来确定母体群体的修改的最大似然估计，并且计算所估计的亲本群体的多样性度量以描述系统。

84. 发明申请

WO2016210241A1 CANCER THERAPY TARGETING TETRASPANIN 33 (TSPAN33) IN MYELOID DERIVED SUPPRESSOR CELLS 审中-公开
标题翻译：癌症治疗TETRASPANIN 33（TSPAN33）在MYELOID衍生的抑制细胞中
公开(公告)号：WO2016210241A1
公开(公告)日：2016-12-29
申请号：PCT/US2016/039201
申请日：2016-06-24
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： SUKHATME, Vikas P. , HUSAIN, Zaheed
IPC分类号： G01N33/00 , G01N33/574 , A61P35/00 , A61K39/395
CPC分类号： A61K39/39566 , A61K39/39558 , A61K2039/505 , A61K2300/00 , A61P35/00 , C07K16/18 , G01N33/5047 , G01N33/5088 , G01N33/56972 , G01N33/57484 , G01N2800/52
摘要： Methods for treating cancer, e.g., in conjunction with anti-cancer therapy, like immunotherapy, and for identifying candidate therapeutic agents, by targeting myeloid derived suppressor cells expressing Tspan33.
摘要翻译：通过靶向表达Tspan33的骨髓来源的抑制细胞来治疗癌症的方法，例如结合抗癌治疗，如免疫治疗，以及用于鉴定候选治疗剂。

85. 发明申请

WO2016161378A1 OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS 审中-公开
标题翻译：用于治疗前列腺素和其他抗原性疾病的寡核苷酸化合物
公开(公告)号：WO2016161378A1
公开(公告)日：2016-10-06
申请号：PCT/US2016/025731
申请日：2016-04-01
申请人： UNIVERSITY OF MASSACHUSETTS , BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： KHVOROVA, Anastasia , MOORE, Melissa , TURANOV, Anton, A. , KARUMANCHI, Ananth
IPC分类号： C12N15/113 , A61K31/712 , A61K31/7125 , A61K31/713 , A61P9/00
CPC分类号： C12N15/1138 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/346 , C12N2310/351 , C12N2310/50
摘要： This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
摘要翻译：本公开涉及血管生成障碍的新靶标。还提供了新的寡核苷酸。还提供了使用该新型寡核苷酸治疗血管生成障碍（例如先兆子痫）的方法。

86. 发明申请

WO2016073357A1 NOVEL HYDROGEN PEROXIDE-ACTIVABLE, ANTI-OXIDANT COMPOUNDS AND METHODS USING SAME 审中-公开
标题翻译：新型过氧化氢活化剂，抗氧化剂及其使用方法
公开(公告)号：WO2016073357A1
公开(公告)日：2016-05-12
申请号：PCT/US2015/058619
申请日：2015-11-02
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , CHONBUK NATIONAL UNIVERSITY INDUSTRIAL COOPERATION FOUNDATION
发明人： KANG, Peter M. , LEE, Dongwon , PARK, Seunggyu , JEONG, Dahee
IPC分类号： C07F5/02 , A61K47/48 , B82Y30/00 , A61K31/69 , A61P29/00
CPC分类号： C07F5/025 , A61K9/5031 , A61K31/69 , A61P29/00
摘要： The present invention includes 4-(hydroxymethyl)phenylboronic esters, which react with hydrogen peroxide to form 4-hydroxybenzyl alcohol, which is an anti-inflammatory and/or anti-oxidant compound. In certain embodiments, the compositions of the invention may be used to treat or prevent oxidative stress and/or inflammation, including ischemic disease.
摘要翻译：本发明包括与过氧化氢反应形成4-羟基苄醇的4-（羟甲基）苯基硼酸酯，其是抗炎和/或抗氧化剂。在某些实施方案中，本发明的组合物可用于治疗或预防氧化应激和/或炎症，包括缺血性疾病。

87. 发明申请

WO2015168416A1 METHODS FOR DETERMINATION OF BIOACTIVITY, REMOVAL, OR INACTIVATION CEREAL AMYLASE TRYPSIN INHIBITORS IN CEREALS, FLOURS AND COMPLEX FOODS 审中-公开
标题翻译：用于确定谷物，食品和复合食品中生物活性，去除或灭活谷氨酰胺酶抑制剂的方法
公开(公告)号：WO2015168416A1
公开(公告)日：2015-11-05
申请号：PCT/US2015/028535
申请日：2015-04-30
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： SCHUPPAN, Detlef
IPC分类号： A23J1/12 , A23L1/015 , C07K1/14
CPC分类号： A23L5/28 , A23L5/23 , A23V2002/00 , A23Y2220/71 , A23Y2220/81
摘要： The present invention features methods of extracting amylase trypsin inhibitors (ATIs) from processed and unprocessed foodstuff, determining bioactivity of ATIs, qualifying the amount of ATIs in a foodstuff, and reducing the content of ATIs in a foodstuff.
摘要翻译：本发明的特征在于从加工和未加工的食品中提取淀粉酶胰蛋白酶抑制剂（ATI）的方法，确定ATI的生物活性，限定食品中ATI的量，并降低食品中ATI的含量。

88. 发明申请

WO2015106129A1 DIAGNOSIS OF CHRONIC LIVER DISEASES 审中-公开
标题翻译：诊断慢性肝病
公开(公告)号：WO2015106129A1
公开(公告)日：2015-07-16
申请号：PCT/US2015/010859
申请日：2015-01-09
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： SCHUPPAN, Detlef , LIBERMANN, Towia , DILLON, Simon, T. , PAPOU, Yury
IPC分类号： C07K14/435 , C07K16/18 , G01N33/53
CPC分类号： G01N33/6893 , C07K14/435 , C12Q1/6883 , C12Q2600/158 , G01N2800/085
摘要： A method of diagnosing a liver disease comprises the steps of: a) obtaining a biological sample from a human or animal subject, b) determining one or more biomarkers that are associated with said liver disease, c) measuring the level of said one or more biomarkers in said biological sample, d) comparing said level of said one or more biomarkers to a control level of said one or more biomarkers, and e) providing a treatment for said liver disease in said human or animal subject to a differing level of at least one of said one or more biomarkers has been detected based on analyzing the above steps, wherein said biomarker is a protein or a peptide fragment thereof selected from the group consisting of: Kininogen-1, Nesprin-1, Vitronectin, Nieman-Pick C1 -like protein 1, Protocadherin Fat 4, Probable E3 ubiquitin- protein ligase HERC2, Extracellular matrix protein FRAS1, E3 ubiquitin-protein ligase UBR3, WD repeat-containing protein 90, Ephrin type-B receptor 3, Probable E3 ubiquitin-protein ligase MYCBP2, Transient receptor potential cation channel subfamily M member 4, Protein FAM71 B, WD repeat-containing protein 85, E3 ubiquitin-protein ligase UBR2, Transmembrane protein 206, Mucin-6, Myotubularin-related protein 9, Nick-associated protein 1, vesicular glutamate transporter 2, Arf-GAP with GTPase, ANK repeat and PH domain containing protein 3, Slit homolog 2 protein, Beta-1,3-galactosyl-0-glycosyl- glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase 7, Fibronectin type III domain containing protein 3C1, and Homeobox even-skipped homolog protein 1, a nucleic acid encoding said protein, or a microRNA specifically regulating the expression of said protein at an RNA level.
摘要翻译：一种诊断肝病的方法包括以下步骤：a）从人或动物受试者获得生物样品，b）确定与所述肝脏疾病相关的一种或多种生物标志物，c）测量所述一种或多种所述生物样品中的生物标志物，d）将所述一种或多种生物标志物的水平与所述一种或多种生物标志物的对照水平进行比较，和e）在所述人或动物中对所述肝脏疾病提供治疗，基于上述步骤的分析已经检测到所述一种或多种生物标志物中的至少一种，其中所述生物标志物是选自以下的蛋白质或其肽片段：Kininogen-1，Nesprin-1，Vitronectin，Nieman-Pick C1 样蛋白1，原载脂蛋白脂肪4，可能的E3泛素蛋白连接酶HERC2，细胞外基质蛋白FRAS1，E3泛素蛋白连接酶UBR3，含WD重复蛋白90，Ephrin B型受体3，可能的E3泛素蛋白在连接酶MYCBP2中，瞬时受体电位阳离子通道亚族M成员4，蛋白FAM71B，WD重复含蛋白85，E3泛素 - 蛋白连接酶UBR2，跨膜蛋白206，粘蛋白-6，肌节蛋白相关蛋白9，尼克蛋白相关蛋白 1，囊泡谷氨酸转运蛋白2，具有GTP酶的Arf-GAP，含有蛋白质3的ANK重复和PH结构域，狭缝同系物2蛋白，β-1,3-半乳糖基-O-糖基 - 糖蛋白β-1,6-N-乙酰基 - 葡聚糖氨基转移酶7，含有蛋白质3C1的纤连蛋白III型结构域，以及Homeobox偶跳同源蛋白1，编码所述蛋白质的核酸或特异性调节所述蛋白质在RNA水平的表达的微小RNA。

89. 发明申请

WO2014204585A1 METHODS FOR TREATMENT OF CARDIOMYOPATHY 审中-公开
标题翻译：治疗心脏病的方法
公开(公告)号：WO2014204585A1
公开(公告)日：2014-12-24
申请号：PCT/US2014/036593
申请日：2014-05-02
申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： MACRAE, Calum , SAFFITZ, Jeffrey
IPC分类号： G01N33/53
CPC分类号： A61K31/404 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2227/108 , A01K2227/40 , A01K2267/0375 , A61K31/4015 , C07K14/47 , G01N33/5061 , G01N33/6887 , G01N2333/47 , G01N2800/325 , G01N2800/50 , G01N2800/52
摘要： The methods and assays described herein related to the diagnosis, prognosis and treatment of cardiomyopathy, e.g. arrhythmia. As described herein, the inventors have discovered that certain compounds can be used to treat cardiomyopathies. These compounds are demonstrated herein to reduce expression of nppb, reduce bradycardia, improve contractility, and increase survival. Notably, provided herein is data demonstrating that administration of these compounds can both prevent the development of symptoms when administered prophylactically and reduce symptom severity in subjects where it is administered after the development of symptoms.
摘要翻译：本文所述的方法和测定涉及心肌病的诊断，预后和治疗，例如，心律失常。如本文所述，发明人已经发现某些化合物可用于治疗心肌病。这些化合物在本文中被证明可以减少nppb的表达，减少心动过缓，改善收缩性和增加存活率。值得注意的是，这里提供的数据表明，这些化合物的施用既可以预防性地预防症状的发展，也可以减轻症状发生后的给药对象的症状严重性。

90. 发明申请

WO2014152622A1 MIRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSIS AND THERAPY 审中-公开
标题翻译： MIRNA生物学在诊断和治疗方面
公开(公告)号：WO2014152622A1
公开(公告)日：2014-09-25
申请号：PCT/US2014/027541
申请日：2014-03-14
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： KALLURI, Raghu , MELO, Sonia
IPC分类号： C12Q1/68 , C12N15/11 , A61K48/00
CPC分类号： C12N15/113 , C07K14/4703 , C12N2310/14 , C12N2310/141 , C12Q1/6886 , C12Q2600/158 , C12Q2600/178 , G01N33/57488 , G01N2333/4704 , G06F19/18 , Y02A90/26
摘要： Methods for diagnosis and treatment of cancers by use of exosomes comprsing miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.
摘要翻译：通过使用包含miRNA及其前体的外来体来诊断和治疗癌症的方法。例如，在一些方面，可以通过确定来自受试者的样品中的外来体的miRNA含量或通过检测外来体中的miRNA加工来诊断或评估癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式